Treatment decisions and contemporary versus pending treatments for hepatitis C

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis C (CHC) treatment aims to prevent disease progression and reduce mortality.
• Interferon (IFN)-based therapies have shown benefits but are associated with complexities and adverse effects.
• Emerging direct-acting antiviral (DAA) regimens offer potent, pan-genotypic treatment options.

Purpose of the Study:

• To critically examine the application of current antiviral regimens, including PEG-IFN, ribavirin, and DAAs, in CHC patients.
• To address the complexities and emerging data not yet reflected in current guidelines.
• To summarize challenges faced by physicians and patients in CHC treatment decisions.

Main Methods:

• Review of current literature and guidelines on CHC antiviral therapy.
• Analysis of treatment response rates and adverse events associated with different regimens.
• Examination of treatment considerations based on disease severity, particularly cirrhosis.

Main Results:

• Response rates to IFN-based treatments correlate with improved mortality outcomes.
• First-generation protease inhibitors combined with IFN show improved response rates for HCV genotype 1.
• DAA regimens necessitate a re-evaluation of existing treatment strategies.
• Patients with cirrhosis have reduced response rates and increased risks of adverse events.

Conclusions:

• Treatment decisions for CHC require careful consideration of regimen efficacy, adverse effects, and patient-specific factors.
• Current guidelines may not fully encompass the implications of newer DAA therapies.
• Deferring treatment for patients with mild CHC may be a reasonable option given the balance of risks and benefits.